Anavex Life Sciences Reports Positive Results in Parkinson’s Disease Study
Anavex Life Sciences recently announced promising results from a 48-week Phase 2 extension study involving their lead drug candidate, ANAVEX®2-73, aimed at treating Parkinson’s disease dementia. The biopharmaceutical company, known for its focus on neurodegenerative and neurodevelopmental disorders, reported that the study met both its primary and secondary objectives, showing significant clinical benefits. The study, […]